Lakeshore Biopharma (LSB) Competitors

SCYNEXIS (NASDAQ:SCYX) and Lakeshore Biopharma (NASDAQ:LSB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, dividends, institutional ownership, community ranking and analyst recommendations.

Do institutionals & insiders have more ownership in SCYX or LSB?

54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 52.6% of Lakeshore Biopharma shares are held by institutional investors. 4.9% of SCYNEXIS shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has more risk and volatility, SCYX or LSB?

SCYNEXIS has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500. Comparatively, Lakeshore Biopharma has a beta of 0.59, meaning that its stock price is 41% less volatile than the S&P 500.

Does the media refer more to SCYX or LSB?

In the previous week, SCYNEXIS and SCYNEXIS both had 2 articles in the media. SCYNEXIS's average media sentiment score of 1.42 beat Lakeshore Biopharma's score of 0.94 indicating that SCYNEXIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SCYNEXIS	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lakeshore Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has higher earnings and valuation, SCYX or LSB?

SCYNEXIS has higher earnings, but lower revenue than Lakeshore Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$2.63M	13.12	$67.04M	-$0.56	-1.58
Lakeshore Biopharma	$672.27M	0.01	-$61.09M	N/A	N/A

Is SCYX or LSB more profitable?

Lakeshore Biopharma has a net margin of 0.00% compared to SCYNEXIS's net margin of -425.41%. Lakeshore Biopharma's return on equity of 0.00% beat SCYNEXIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-425.41%	-66.21%	-38.84%
Lakeshore Biopharma	N/A	N/A	N/A

Does the MarketBeat Community prefer SCYX or LSB?

SCYNEXIS received 505 more outperform votes than Lakeshore Biopharma when rated by MarketBeat users.

Company	Underperform	Outperform
SCYNEXIS	Outperform Votes 505 69.56%	Underperform Votes 221 30.44%
Lakeshore Biopharma	N/A	N/A

Summary

SCYNEXIS beats Lakeshore Biopharma on 7 of the 11 factors compared between the two stocks.